{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T04:17:15Z","timestamp":1787977035203,"version":"build-2784847793"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T00:00:00Z","timestamp":1787961600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T00:00:00Z","timestamp":1787961600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100002657","name":"Istanbul \u00dcniversitesi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002657","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"DOI":"10.1007\/s11255-026-05348-1","type":"journal-article","created":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T03:25:16Z","timestamp":1787973916000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The expression and prognostic significance of immune checkpoint molecules across clear cell, papillary and chromophobe renal cell carcinoma subtypes"],"prefix":"10.1007","author":[{"given":"Serdar","family":"Turan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3514-1394","authenticated-orcid":false,"given":"Selcuk","family":"Erdem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ozge","family":"Hurdogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasemin","family":"Ozluk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rifat Burak","family":"Ergul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oner","family":"Sanli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faruk","family":"Ozcan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,29]]},"reference":[{"issue":"7","key":"5348_CR1","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1200\/JCO.2003.02.005","volume":"21","author":"EM Messing","year":"2003","unstructured":"Messing EM, Manola J, Wilding G et al (2003) Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group\/Intergroup trial. J Clin Oncol 21(7):1214\u20131222. https:\/\/doi.org\/10.1200\/JCO.2003.02.005","journal-title":"J Clin Oncol"},{"issue":"1","key":"5348_CR2","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ejca.2013.08.019","volume":"50","author":"M Aitchison","year":"2014","unstructured":"Aitchison M, Bray CA, Van Poppel H et al (2014) Adjuvant 5-fluorouracil, alpha-interferon and interleukin-2 versus observation in patients at high risk of recurrence after nephrectomy for renal cell carcinoma: results of a phase III randomised European Organisation for Research and Treatment of Cancer (Genito-Urinary Cancers Group)\/National Cancer Research Institute trial. Eur J Cancer 50(1):70\u201377. https:\/\/doi.org\/10.1016\/j.ejca.2013.08.019","journal-title":"Eur J Cancer"},{"issue":"11","key":"5348_CR3","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1016\/j.urolonc.2021.07.022","volume":"39","author":"E Laukhtina","year":"2021","unstructured":"Laukhtina E, Quhal F, Mori K et al (2021) Adjuvant therapy with tyrosine kinase inhibitors for localized and locally advanced renal cell carcinoma: an updated systematic review and meta-analysis. Urol Oncol 39(11):764\u2013773. https:\/\/doi.org\/10.1016\/j.urolonc.2021.07.022","journal-title":"Urol Oncol"},{"issue":"8","key":"5348_CR4","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1056\/NEJMoa2106391","volume":"385","author":"TK Choueiri","year":"2021","unstructured":"Choueiri TK, Tomczak P, Park SH et al (2021) Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma. N Engl J Med 385(8):683\u2013694. https:\/\/doi.org\/10.1056\/NEJMoa2106391","journal-title":"N Engl J Med"},{"issue":"15","key":"5348_CR5","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1056\/NEJMoa2312695","volume":"390","author":"TK Choueiri","year":"2024","unstructured":"Choueiri TK, Tomczak P, Park SH et al (2024) Overall survival with adjuvant pembrolizumab in renal-cell carcinoma. N Engl J Med 390(15):1359\u20131371. https:\/\/doi.org\/10.1056\/NEJMoa2312695","journal-title":"N Engl J Med"},{"issue":"10379","key":"5348_CR6","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/S0140-6736(22)02574-0","volume":"401","author":"RJ Motzer","year":"2023","unstructured":"Motzer RJ, Russo P, Gr\u00fcnwald V et al (2023) Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial. Lancet 401(10379):821\u2013832. https:\/\/doi.org\/10.1016\/S0140-6736(22)02574-0","journal-title":"Lancet"},{"issue":"2","key":"5348_CR7","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1200\/JCO.24.00773","volume":"43","author":"RJ Motzer","year":"2025","unstructured":"Motzer RJ, Russo P, Bex A et al (2025) Adjuvant nivolumab monotherapy vs placebo for localized renal cell carcinoma at high risk of relapse after nephrectomy: results from Part B of the randomized phase 3 CheckMate 914 trial. J Clin Oncol 43(2):189\u2013200. https:\/\/doi.org\/10.1200\/JCO.24.00773","journal-title":"J Clin Oncol"},{"issue":"10358","key":"5348_CR8","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1016\/S0140-6736(22)01658-0","volume":"400","author":"SK Pal","year":"2022","unstructured":"Pal SK, Uzzo R, Karam JA et al (2022) Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial. Lancet 400(10358):1103\u20131116. https:\/\/doi.org\/10.1016\/S0140-6736(22)01658-0","journal-title":"Lancet"},{"issue":"6","key":"5348_CR9","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.eururo.2025.02.020","volume":"87","author":"A Bex","year":"2025","unstructured":"Bex A, Ghanem YA, Albiges L, Bonn S, Campi R, Capitanio U et al (2025) European association of urology guidelines on renal cell carcinoma: the 2025 update. Eur Urol 87(6):683\u2013696. https:\/\/doi.org\/10.1016\/j.eururo.2025.02.020","journal-title":"Eur Urol"},{"issue":"1","key":"5348_CR10","doi-asserted-by":"publisher","first-page":"4","DOI":"10.6004\/jnccn.2024.0008","volume":"22","author":"RJ Motzer","year":"2024","unstructured":"Motzer RJ, Jonasch E, Agarwal N, Alva A, Bagshaw H, Baine M et al (2024) NCCN guidelines\u00ae insights: kidney cancer, version 2. J Natl Compr Canc Netw 22(1):4\u201316. https:\/\/doi.org\/10.6004\/jnccn.2024.0008","journal-title":"J Natl Compr Canc Netw"},{"issue":"5","key":"5348_CR11","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.eururo.2022.06.016","volume":"82","author":"H Moch","year":"2022","unstructured":"Moch H, Amin MB, Berney DM et al (2022) The 2022 World Health Organization classification of tumours of the urinary system and male genital organs-Part A: renal, penile, and testicular tumours. Eur Urol 82(5):458\u2013468. https:\/\/doi.org\/10.1016\/j.eururo.2022.06.016","journal-title":"Eur Urol"},{"issue":"1","key":"5348_CR12","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1186\/s13059-016-1092-z","volume":"17","author":"Y Senbabao\u011flu","year":"2016","unstructured":"Senbabao\u011flu Y, Gejman RS, Winer AG et al (2016) Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures. Genome Biol 17(1):231. https:\/\/doi.org\/10.1186\/s13059-016-1092-z","journal-title":"Genome Biol"},{"issue":"1","key":"5348_CR13","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1097\/COC.0000000000000239","volume":"39","author":"EI Buchbinder","year":"2016","unstructured":"Buchbinder EI, Desai A (2016) CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition. Am J Clin Oncol 39(1):98\u2013106. https:\/\/doi.org\/10.1097\/COC.0000000000000239","journal-title":"Am J Clin Oncol"},{"issue":"12","key":"5348_CR14","doi-asserted-by":"publisher","first-page":"2341","DOI":"10.1016\/j.str.2015.09.010","volume":"23","author":"KM Zak","year":"2015","unstructured":"Zak KM, Kitel R, Przetocka S et al (2015) Structure of the complex of human programmed death 1, PD-1, and its ligand PD-L1. Structure 23(12):2341\u20132348. https:\/\/doi.org\/10.1016\/j.str.2015.09.010","journal-title":"Structure"},{"key":"5348_CR15","doi-asserted-by":"publisher","DOI":"10.1177\/17588359231220510","volume":"16","author":"N Krishnamurthy","year":"2024","unstructured":"Krishnamurthy N, Nishizaki D, Lippman SM et al (2024) High CTLA-4 transcriptomic expression correlates with high expression of other checkpoints and with immunotherapy outcome. Ther Adv Med Oncol 16:17588359231220510. https:\/\/doi.org\/10.1177\/17588359231220510","journal-title":"Ther Adv Med Oncol"},{"issue":"1","key":"5348_CR16","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.eururo.2016.02.029","volume":"70","author":"H Moch","year":"2016","unstructured":"Moch H, Cubilla AL, Humphrey PA et al (2016) The 2016 WHO classification of tumours of the urinary system and male genital organs-Part A: renal, penile, and testicular tumours. Eur Urol 70(1):93\u2013105. https:\/\/doi.org\/10.1016\/j.eururo.2016.02.029","journal-title":"Eur Urol"},{"issue":"2","key":"5348_CR17","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3322\/caac.21388","volume":"67","author":"MB Amin","year":"2017","unstructured":"Amin MB, Greene FL, Edge SB et al (2017) The eighth edition AJCC Cancer Staging Manual: continuing to build a bridge from a population-based to a more \u201cpersonalized\u201d approach to cancer staging. CA Cancer J Clin 67(2):93\u201399. https:\/\/doi.org\/10.3322\/caac.21388","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"5348_CR18","doi-asserted-by":"publisher","first-page":"367","DOI":"10.21037\/tau.2020.01.21","volume":"9","author":"Y Lu","year":"2020","unstructured":"Lu Y, Song Y, Xu Y et al (2020) The prevalence and prognostic and clinicopathological value of PD-L1 and PD-L2 in renal cell carcinoma patients: a systematic review and meta-analysis involving 3,389 patients. Transl Androl Urol 9(2):367\u2013381. https:\/\/doi.org\/10.21037\/tau.2020.01.21","journal-title":"Transl Androl Urol"},{"issue":"11","key":"5348_CR19","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1093\/annonc\/mdu445","volume":"25","author":"TK Choueiri","year":"2014","unstructured":"Choueiri TK, Fay AP, Gray KP et al (2014) PD-L1 expression in nonclear-cell renal cell carcinoma. Ann Oncol 25(11):2178\u20132184. https:\/\/doi.org\/10.1093\/annonc\/mdu445","journal-title":"Ann Oncol"},{"issue":"1","key":"5348_CR20","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.clgc.2020.07.002","volume":"19","author":"F Erlmeier","year":"2021","unstructured":"Erlmeier F, Steffens S, St\u00f6hr C et al (2021) Characterization of PD-1 and PD-L1 expression in papillary renal cell carcinoma: results of a large multicenter study. Clin Genitourin Cancer 19(1):53-59.e1. https:\/\/doi.org\/10.1016\/j.clgc.2020.07.002","journal-title":"Clin Genitourin Cancer"},{"issue":"11","key":"5348_CR21","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-016-0833-x","volume":"33","author":"F Erlmeier","year":"2016","unstructured":"Erlmeier F, Hartmann A, Autenrieth M et al (2016) PD-1\/PD-L1 expression in chromophobe renal cell carcinoma: an immunological exception? Med Oncol 33(11):120. https:\/\/doi.org\/10.1007\/s12032-016-0833-x","journal-title":"Med Oncol"},{"issue":"7","key":"5348_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25073916","volume":"25","author":"M Chraba\u0144ska","year":"2024","unstructured":"Chraba\u0144ska M, Szweda-Gandor N, Rynkiewicz M et al (2024) Association between PD-L1 expression and the prognosis and clinicopathologic features of non-clear cell renal cell carcinoma. Int J Mol Sci 25(7):3916. https:\/\/doi.org\/10.3390\/ijms25073916","journal-title":"Int J Mol Sci"},{"key":"5348_CR23","doi-asserted-by":"publisher","first-page":"17174","DOI":"10.1073\/pnas.0406351101","volume":"101","author":"RH Thompson","year":"2004","unstructured":"Thompson RH, Gillett MD, Cheville JC et al (2004) Costimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci USA 101:17174\u201317179","journal-title":"Proc Natl Acad Sci USA"},{"key":"5348_CR24","doi-asserted-by":"publisher","first-page":"3381","DOI":"10.1158\/0008-5472.CAN-05-4303","volume":"66","author":"RH Thompson","year":"2006","unstructured":"Thompson RH, Kuntz SM, Leibovich BC et al (2006) Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res 66:3381\u20133385","journal-title":"Cancer Res"},{"issue":"12","key":"5348_CR25","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/nrclinonc.2017.101","volume":"14","author":"WH Fridman","year":"2017","unstructured":"Fridman WH, Zitvogel L, Saut\u00e8s-Fridman C et al (2017) The immune contexture in cancer prognosis and treatment. Nat Rev Clin Oncol 14(12):717\u2013734. https:\/\/doi.org\/10.1038\/nrclinonc.2017.101","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"5348_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8050743","volume":"8","author":"A Kahlmeyer","year":"2019","unstructured":"Kahlmeyer A, St\u00f6hr CG, Hartmann A et al (2019) Expression of PD-1 and CTLA-4 are negative prognostic markers in renal cell carcinoma. J Clin Med 8(5):743. https:\/\/doi.org\/10.3390\/jcm8050743","journal-title":"J Clin Med"},{"key":"5348_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-020-01603-2","volume":"20","author":"S Liu","year":"2020","unstructured":"Liu S, Wang F, Tan W et al (2020) CTLA4 has a profound impact on the landscape of tumor-infiltrating lymphocytes with a high prognosis value in clear cell renal cell carcinoma (ccRCC). Cancer Cell Int 20:519. https:\/\/doi.org\/10.1186\/s12935-020-01603-2","journal-title":"Cancer Cell Int"},{"issue":"14","key":"5348_CR28","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","volume":"378","author":"RJ Motzer","year":"2018","unstructured":"Motzer RJ, Tannir NM, McDermott DF et al (2018) Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med 378(14):1277\u20131290. https:\/\/doi.org\/10.1056\/NEJMoa1712126","journal-title":"N Engl J Med"},{"issue":"7-8","key":"5348_CR29","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1159\/000506296","volume":"104","author":"M Shen","year":"2020","unstructured":"Shen M, Chen G, Xie Q et al (2020) Association between PD-L1 expression and the prognosis and clinicopathologic features of renal cell carcinoma: a systematic review and meta-analysis. Urol Int 104(7\u20138):533\u2013541. https:\/\/doi.org\/10.1159\/000506296","journal-title":"Urol Int"},{"issue":"2","key":"5348_CR30","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s10147-022-02256-z","volume":"28","author":"S Tamada","year":"2023","unstructured":"Tamada S, Nozawa M, Ohba K et al (2023) Prognostic value of PD-L1 expression in recurrent renal cell carcinoma after nephrectomy: a secondary analysis of the ARCHERY study. Int J Clin Oncol 28(2):289\u2013298. https:\/\/doi.org\/10.1007\/s10147-022-02256-z","journal-title":"Int J Clin Oncol"},{"issue":"9","key":"5348_CR31","first-page":"14595","volume":"8","author":"F Xu","year":"2015","unstructured":"Xu F, Xu L, Wang Q et al (2015) Clinicopathological and prognostic value of programmed death ligand-1 (PD-L1) in renal cell carcinoma: a meta-analysis. Int J Clin Exp Med 8(9):14595\u201314603","journal-title":"Int J Clin Exp Med"},{"issue":"11","key":"5348_CR32","doi-asserted-by":"publisher","first-page":"2667","DOI":"10.1007\/s00345-022-04153-6","volume":"40","author":"G Fallara","year":"2022","unstructured":"Fallara G, Larcher A, Rosiello G et al (2022) How to optimize the use of adjuvant pembrolizumab in renal cell carcinoma: which patients benefit the most? World J Urol 40(11):2667\u20132673. https:\/\/doi.org\/10.1007\/s00345-022-04153-6","journal-title":"World J Urol"},{"issue":"2","key":"5348_CR33","doi-asserted-by":"publisher","first-page":"3355","DOI":"10.18632\/oncotarget.13765","volume":"8","author":"XH Ning","year":"2017","unstructured":"Ning XH, Gong YQ, He SM et al (2017) Higher programmed cell death 1 ligand 1 (PD-L1) mRNA level in clear cell renal cell carcinomas is associated with a favorable outcome due to the active immune responses in tumor tissues. Oncotarget 8(2):3355\u20133363. https:\/\/doi.org\/10.18632\/oncotarget.13765","journal-title":"Oncotarget"},{"issue":"7","key":"5348_CR34","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/j.annonc.2025.03.016","volume":"36","author":"L Bergmann","year":"2025","unstructured":"Bergmann L, Albiges L, Ahrens M et al (2025) Prospective randomized phase-II trial of ipilimumab\/nivolumab versus standard of care in non-clear cell renal cell cancer: results of the SUNNIFORECAST trial. Ann Oncol 36(7):796\u2013806. https:\/\/doi.org\/10.1016\/j.annonc.2025.03.016","journal-title":"Ann Oncol"},{"issue":"Suppl 2","key":"5348_CR35","doi-asserted-by":"publisher","first-page":"S1635","DOI":"10.1016\/j.annonc.2025.09.110","volume":"36","author":"J Larkin","year":"2025","unstructured":"Larkin J, Powles TB, Frangou E et al (2025) First results from RAMPART: an international phase III randomised-controlled trial of adjuvant durvalumab monotherapy or combined with tremelimumab for resected primary renal cell carcinoma (RCC) led by MRC CTU at UCL. Ann Oncol 36(Suppl 2):S1635. https:\/\/doi.org\/10.1016\/j.annonc.2025.09.110","journal-title":"Ann Oncol"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-026-05348-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-026-05348-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-026-05348-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T03:25:18Z","timestamp":1787973918000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-026-05348-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,29]]},"references-count":35,"alternative-id":["5348"],"URL":"https:\/\/doi.org\/10.1007\/s11255-026-05348-1","relation":{},"ISSN":["1573-2584"],"issn-type":[{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,29]]},"assertion":[{"value":"25 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of Istanbul University, Istanbul Faculty of Medicine (approval number 2023\/1442). The study was conducted in accordance with the ethical standards of the institutional and national research committee and with the 1964 Declaration of Helsinki and its later amendments.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The requirement for informed consent was waived by the ethics committee because of the retrospective design of the study.","order":3,"name":"Ethics","label":"Patient informed consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}}]}}